ROBERT C. YOUNG, M.D., F.A.C.P.; VINCENT T. DEVITA JR., M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The Southwest Cancer Chemotherapy Study Group's article on the chemotherapy of advanced Hodgkin's disease with mechlorethamine, vincristine [Oncovin®], procarbazine, and prednisone (MOPP) (Ann Intern Med 79:376-382, 1973) confirms many of our initial observations: complete remission rates with MOPP (1) ; the compromise contributed by previous chemotherapy (2); the good response to MOPP after previous radiotherapy (3); the long, disease-free period after complete remission with MOPP; and the long-term, disease-free survival after such treatment (4). Although the authors stress the benefits of maintenance therapy, their study also confirms the lack of benefit this therapy has on the survival
YOUNG RC, DEVITA VT. Therapy for Hodgkin's Disease. Ann Intern Med. 1974;80:274–275. doi: https://doi.org/10.7326/0003-4819-80-2-274
Download citation file:
Published: Ann Intern Med. 1974;80(2):274-275.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use